Halozyme Therapeutics Says Following Decision By European Patent OPffice To Revoke One OF Janssen's Co-Formulation Patents For DARZALEX, It Projects No Impact On US Or European Royalty Revenues From DARZALEX FASPRO And SC Through 2032 And Reaffirms Guidance
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics announced that the European Patent Office's decision to revoke a Janssen co-formulation patent for DARZALEX will not impact its US or European royalty revenues from DARZALEX FASPRO and SC through 2032. The company reaffirmed its guidance.
October 24, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Halozyme Therapeutics expects no impact on its royalty revenues from DARZALEX FASPRO and SC in the US and Europe through 2032, following a European patent revocation.
The European Patent Office's decision to revoke a Janssen patent could have raised concerns about potential revenue impacts. However, Halozyme has clarified that its royalty revenues from DARZALEX FASPRO and SC will remain unaffected through 2032, maintaining investor confidence and reaffirming its guidance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80